Two ARLG PI-Initiated, Laboratory-Based Trials Reached Database Lock

ARLG Principal Investigators Ritu Banerjee, MD, PhD of Vanderbilt University and Audrey Schuetz, MD, MPH, D (ABMM) of Mayo Clinic have successfully led the RAPIDS-GN and DISK trials, respectively, to completion.

The primary objective of RAPIDS-GN is to evaluate the impact of rapid identification and antimicrobial susceptibility testing (AST) on the time to first antibiotic modification in the first 72 hours after randomization. RAPIDS-GN enrolled 500 subjects in two sites over 1 year. Database lock occurred in March 2019. Dr. Banerjee expects to present the preliminary results at the American Society for Microbiology (ASM) Microbe meeting in June 2019.

The primary objective of the DISK trial is to evaluate the performance of a rapid disk diffusion test performed using positive blood culture broth (BCB) as the inoculum, read at 16-18 hours of incubation. The project enrolled 500 subjects across five sites over 7 months. Database lock occurred in February 2019. Dr. Schuetz expects to present preliminary results at the Clinical & Laboratory Standards Institute (CLSI) meeting in June 2019.

Congratulations to both ARLG PIs and study sites on this accomplishment. We are looking forward to the results for answering these important questions.